Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ninjurin-1 neutralizing antibody
- Development stage
- Preclinical
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intraperitoneal, Intravenous
01
Overview
Ninjurin-1 neutralizing antibody refers to monoclonal antibodies designed to target and inhibit nerve injury-induced protein 1 (Ninjurin-1 or Ninj1). Ninjurin-1 is a cell-surface adhesion molecule that is upregulated after nerve injury and is also a critical mediator of plasma membrane rupture (PMR) during lytic cell death (such as pyroptosis, necroptosis, and ferroptosis). By blocking Ninjurin-1, these neutralizing antibodies inhibit cell lysis, prevent the release of pro-inflammatory damage-associated molecular patterns (DAMPs), and promote tissue repair. Preclinical research has demonstrated that Ninjurin-1 neutralizing antibodies can restore bladder function in spinal cord injury models, improve erectile function in diabetic and cavernous nerve injury models, and reduce inflammation in models of gout and liver injury.
- Other names
- Ninj1 neutralizing antibodyNinj-1 neutralizing antibodyNinj 1 neutralizing antibodyNinj1-AbNinj-1-AbNinj 1-Abanti-NINJ1 antibodyanti-NINJ-1 antibodyanti-NINJ 1 antibodyanti-Ninjurin-1 antibodyanti-Ninjurin1 antibodyanti-Ninjurin 1 antibodyanti-Ninjurin-1 neutralizing antibodyanti-Ninjurin1 neutralizing antibodyanti-Ninjurin 1 neutralizing antibody
02
Targets
NINJ1 (Nerve injury-induced protein 1)
Beyond the preview
Go deeper on Ninjurin-1 neutralizing antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ninjurin-1 neutralizing antibody.